Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded on December 11, 2020 and is headquartered in Cupertino, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2024 and summarized recent business highlights.

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking place November 10-13, in Boston, Massachusetts.

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, 2024, in Rancho Palos Verdes, CA.

Reviva to Participate in the UBS Global Healthcare Conference

CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually October 15-17, 2024.

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference, taking place October 9, 2024, in New York, NY.

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

CUPERTINO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of an underwritten offering of 4,761,905 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and investor warrants to purchase up to 4,761,905 shares of common stock. The combined offering price of each share of common stock and accompanying warrant sold in the offering (including the pricing for the warrant repricing described below) will be equal to $1.05, priced at-the-market under the Nasdaq rules. The combined offering price of each pre-funded warrant and accompanying warrant sold in the offering will be equal to $1.0499. The warrants have an exercise price of $0.7964 per share, will be immediately exercisable and will expire five years following the date of issuance. The pre-funded warrants have an exercise price of $0.0001 per share, will be immediately exercisable and may be exercised at any time after their original issuance. The offering is expected to close on or about August 22, 2024, subject to customary closing conditions.

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD)

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:RVPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 1,898,734 shares of the Company's common stock and warrants to purchase up to 1,898,734 shares of common stock at a combined offering price of $1.58 per share of common stock and accompanying warrant priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $1.455 per share, are immediately exercisable and will expire five years following the date of issuance.

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has entered into a definitive agreement for the sale and issuance of 1,898,734 shares of the Company's common stock and warrants to purchase up to 1,898,734 shares of common stock at a combined offering price of $1.58 per share of common stock and accompanying warrant in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $1.455 per share, will be immediately exercisable and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about May 29, 2024, subject to the satisfaction of customary closing conditions.

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the BIO International Convention, taking place June 3-6, 2024, in San Diego, CA.

Reviva to Participate in the BIO International Convention

– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial expected in Q4 2024 – CUPERTINO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced an enrollment update to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia.

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia –

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present new efficacy data on brilaroxazine in an animal model of idiopathic pulmonary fibrosis as part of a late-breaking poster presentation at the 2024 American Thoracic Society (ATS) International Conference, to be held in San Diego, CA, May 17-22, 2024.

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

NEW YORK , May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Reviva Pharmaceuticals securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

RVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH

CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present new pharmacology data on brilaroxazine as part of two poster presentations at the ASPET 2024 Annual Meeting, to be held in Arlington, VA May 16-19, 2024.

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Reviva Pharmaceuticals securities you may be entitled to compensation without payment of any out of pocket fees.

RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH

- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Topline data from 1-year open-label extension (OLE) long-term safety trial expected in Q4 2024 - CUPERTINO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today it has gained alignment with the U.S. Food and Drug Administration (FDA) on its registrational Phase 3 program for brilaroxazine in schizophrenia.

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia –

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting, to be held in Colorado Springs, CO, USA on March 27-29, 2023.

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a Fireside Chat at the UBS Virtual CNS Day, taking place virtually March 18, 2024.

Reviva to Present at the UBS Virtual CNS Day

CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 36th Annual ROTH Conference, taking place March 17-19, 2024, in Dana Point, CA.

Reviva to Present at the 36th Annual ROTH Conference

CUPERTINO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 2024 BIO CEO & Investor Conference, taking place February 26-27, 2024, in New York, NY.

News for Reviva Pharmaceuticals Stock (RVPH)